Khaldoun Mozahem, MD
Neurology · Bridgeport, WVNPI 1346730504
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,661 of the $1,966 with a category attached, or 84.5%. 28 manufacturers reported payments, led by AbbVie at 24.7% of the total. Reporting peaked in 2022 at $573 and has fallen 88.5% since, to $66 in 2025.
Across 85 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$485
- AstraZeneca$176
- Teva Pharmaceuticals USA, Inc.$143
- Harmony Biosciences LLC$115
- Jazz Pharmaceuticals Inc.$100
- Pfizer$93
- plus $856 from 22 others
What the payments were for
- Food & beverage$1,66184%
- Education$30516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $485 |
| AstraZeneca | 4 | $176 |
| Teva Pharmaceuticals USA, Inc. | 4 | $143 |
| Harmony Biosciences LLC | 3 | $115 |
| Jazz Pharmaceuticals Inc. | 1 | $100 |
| Pfizer | 4 | $93 |
| Axsome Therapeutics, Inc. | 2 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| UCB, Inc. | 3 | $70 |
| Amneal Pharmaceuticals LLC | 4 | $60 |
| Livanova USA, Inc. | 2 | $53 |
| EMD Serono, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $52 |
| Biogen | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 1 | $41 |
| Genentech USA, Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Lundbeck LLC | 2 | $32 |
| SK Life Science, Inc. | 2 | $29 |
| Novartis | 2 | $29 |
| Medtronic | 1 | $26 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Amgen | 1 | $22 |
| Neurelis, Inc. | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$112
How this compares
$1,966 in reported general payments places this provider in the 60th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 21 | $445,707 |
| IngrezzaValbenazine Tosylate | 13 | $112,190 |
| FingolimodFingolimod Hcl | 12 | $51,579 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $28,874 |
| Emgality PenGalcanezumab-Gnlm | 27 | $22,144 |
| Nurtec OdtRimegepant Sulfate | 15 | $20,209 |
| TopamaxTopiramate | 11 | $17,104 |
| QuliptaAtogepant | 12 | $15,002 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 22 | $15,000 |
| Lacosamide | 59 | $11,317 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $10,020 |
| LamictalLamotrigine | 11 | $7,827 |
| Levetiracetam | 135 | $4,443 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 108 | $3,752 |
| Gabapentin | 290 | $3,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $93 | $20,20915 claims |
| AbbVieQulipta | $485 | $15,00212 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $60 | $1,63216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 93 neurology providers in West Virginia.
Other neurology in Bridgeport
- Adnan AlghadbanBridgeport$27K
- Shivshankar NavadaBridgeport$4K
- Barry VaughtCrab Orchard$1.4M
- Paul FergusonHuntington$649K
- Umer NajibMorgantown$246K
- Muhammed Nasher-AlneamCharleston$73K
- Robert LewisHurricane$73K
- Lauren SeebergerCharleston$72K
- Cheryl SmithMorgantown$68K
- Mouhannad AzzouzMorgantown$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.